Active substance
Results for the substance pertuzumab
1 result
About this active substance
Pertuzumab is a humanized monoclonal antibody used in the treatment of HER2-positive breast cancer. It is indicated in combination with other therapies, such as trastuzumab and chemotherapy, for the treatment of metastatic or locally advanced breast cancer, as well as in neoadjuvant therapy (before surgery) to reduce tumor size.
Pertuzumab works by blocking the dimerization of the HER2 receptor with other HER receptors (such as HER3), thereby preventing the activation of intracellular signaling that promotes tumor cell growth and proliferation. This specific action makes pertuzumab an effective targeted therapy for patients with HER2-positive tumors.
It is used in combination with trastuzumab because the two drugs act synergistically to completely block the HER2 receptor, providing better disease control and prolonging patient survival.
Common side effects include diarrhea, nausea, fatigue, hair loss, and infusion-related reactions. In rare cases, more severe effects such as heart failure or severe allergic reactions may occur. For this reason, patients’ cardiac function must be regularly monitored during treatment.
Pertuzumab is administered via intravenous infusion under strict medical supervision. Patients should strictly follow their doctor’s recommendations and inform the medical team about any side effects or other medications being taken.
Pertuzumab works by blocking the dimerization of the HER2 receptor with other HER receptors (such as HER3), thereby preventing the activation of intracellular signaling that promotes tumor cell growth and proliferation. This specific action makes pertuzumab an effective targeted therapy for patients with HER2-positive tumors.
It is used in combination with trastuzumab because the two drugs act synergistically to completely block the HER2 receptor, providing better disease control and prolonging patient survival.
Common side effects include diarrhea, nausea, fatigue, hair loss, and infusion-related reactions. In rare cases, more severe effects such as heart failure or severe allergic reactions may occur. For this reason, patients’ cardiac function must be regularly monitored during treatment.
Pertuzumab is administered via intravenous infusion under strict medical supervision. Patients should strictly follow their doctor’s recommendations and inform the medical team about any side effects or other medications being taken.